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Abstract
Background Vitamin D deficiency is common in the Middle
East and in Saudi Arabia, in particular. While several interna-
tional recommendations on the management of vitamin D defi-
ciency have been documented and practiced globally, these rec-
ommendations should be adapted to the conditions of the
Middle Eastern region. To address this challenge, the Prince
Mutaib Chair for Biomarkers of Osteoporosis (PMCO) in
King Saud University (KSU), Riyadh, KSA, together with local
experts and in cooperation with the European Society for
Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis (ESCEO), organized a panel that formulated
unified recommendations in the diagnosis and treatment of vi-
tamin D deficiency in the region.
Methods The selection of local and international experts com-
menced during the 2nd International Vitamin D Symposium
conducted in Riyadh, Saudi Arabia, last January 20-–21, 2016.
Reviews of the most recent literature were done, and face-to-face
meetings were conducted for revisions and final
recommendations.Results: Vitamin D sufficiency is defined as
circulating serum 25(OH)D ≥50 nmol (≥20 ng/ml) for the gen-
eral population and vitamin D adequacy as serum 25(OH)D >75
nmol/L l (>30 ng/ml) for the frail and osteoporotic elderly.
Despite overwhelming prevalence of vitamin D deficiency,
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universal screening is not recommended. Recommendations for
the general population, children, pregnant/lactatingwomen, post-
menopausal women, the elderly, and those with subsequent met-
abolic diseases were provided.
Results Vitamin D sufficiency is defined as circulating serum
25(OH)D ≥50 nmol (≥20 ng/ml) for the general population and
vitamin D adequacy as serum 25(OH)D >75 nmol/L l (>30 ng/
ml) for the frail and osteoporotic elderly. Despite overwhelming
prevalence of vitamin D deficiency, universal screening is not
recommended. Recommendations for the general population,
children, pregnant/lactating women, post-menopausal women,
the elderly, and those with subsequent metabolic diseases were
provided.
Conclusion Vitamin D supplementation/correction is advised in
all persons whose serum 25(OH)D falls below 50 nmol/l (20 ng/
ml), and achieving a target of 75 nmol/l (30 ng/ml) is particularly
suited for frail, osteoporotic, and older patients. Conductingwell-
designed clinical trials in the region that will address economic
implications and investigations on the treatment persistence and
compliance to vitamin D treatment in the region are encouraged.
Keywords VitaminD . Saudi Arabia . ESCEO .
Recommendations . Consensus
Introduction
During the last decade, no other micronutrient has gained and
sustained massive interest in the fields of health and biomedical
research community as much as vitamin D. As a very active
research area, many of the physiologic effects of vitamin D in
both mineral metabolism and extra-skeletal effects have already
been covered, but not without its own share of controversies,
reinforcing the need for further (despite an abundance of) inves-
tigations. Among the roster of widely debated areas in vitaminD,
the cutoff used for defining vitamin D deficiency, the methods
used formeasuring vitaminD status and formedical practitioners
as well as the informed general public, and the right treatment for
vitamin D deficiency are included.
Given that the management for vitamin D deficiency remains
an evolving focus in biomedical research, several well-
recognized international organizations have created their own
evidence-based guidelines and consensuses for the general public
[1, 2], including recommendations based on harder outcomes
such as the preservation of bone health [3], prevention of frac-
tures [4], and of nutritional rickets [5]. One possible caveat from
the widely used guidelines is that they were tailored mostly for
the European and North American populations whose geograph-
ical location, climate conditions, culture of outdoor social activ-
ities, not to mention the ethnicity itself, vary widely from other
populations. The differences in the factors mentioned, which are
consideredmajor determinants of vitamin D status, therefore cast
doubt on the suitability of some international recommendations
to populations coming from other regions in the world. For in-
stance, the global consensus defines vitamin D deficiency as
serum 25(OH)D < 30 nmol/l [5], while the guidelines and posi-
tion statements adopted in the USA, central Europe, South
America, and Korea define Bdeficiency^ as <50 nmol/l as the
more appropriate cutoff for use in their populations [6–8], twice
the level adopted by the International Osteoporosis Foundation
(IOF), which is <25 nmol/l [9]. The disparities in vitamin D
cutoffs, not to mention the inconsistencies in terms such as defi-
ciency, Binsufficiency,^ Bhypovitaminosis D,^ and
Binadequacy,^ among experts, are just a small fraction in the
litany of other valid arguments (i.e., candidates for vitamin D
screening and supplementation and type of 25(OH)D metabolite
to measure using what method), making this seemingly straight-
forward, easy to treat micronutrient deficiency much more com-
plicated. It is not surprising therefore that some national/regional
societies find it most optimal to tailor the management for vita-
min D deficiency in accordance to what they deem fit for their
population [10, 11].
The need for local guidelines
There is a wealth of epidemiologic evidence that vitamin D de-
ficiency and its concomitant risk factors in the Middle Eastern
region, and the Kingdom of Saudi Arabia (KSA) in particular,
are very common in both children and adults [12–14]. Despite
the overwhelming data, little has been done to address this epi-
demic on a clinical setting. Different vitamin D guidelines from
other parts of the world have been produced, most of which are
dependent on the target disease (osteoporosis, osteomalacia, falls,
etc.) [3–6, 15–17]. The present consensus guidelines are tailored
to geographical location and known risk factors common to the
Saudi general population. Recommendations for the Gulf coun-
tries including Saudi Arabia, with the exception of UAE [18], are
still lacking. These countries are highly reliant on other existing
guidelines, which may prove to be inapplicable to regional set-
tings. Hence, a task force was created to address the vitamin D
deficiency pandemic in the country with the objective of gener-
ating a unified and tailored consensus for KSA residents and
citizens.
PrinceMutaib Chair for Biomarkers of Osteoporosis
task force
The Prince Mutaib Chair for Biomarkers of Osteoporosis
(PMCO) in King Saud University (KSU), Riyadh, KSA, assem-
bled local 12 local experts in the fields of endocrinology, clinical
biochemistry, and clinical nutrition and invited two advisers from
the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO), who are experts in
bone diseases, health economics, and epidemiology. The
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selection of local and international experts commenced during
the 2nd International Vitamin D Symposium conducted in
Riyadh, Saudi Arabia, last January 20–21, 2016. Time frame
and draft outline were discussed.
A survey was also circulated among experts to determine the
experts’ consensus on the most suitable diagnostic cutoff of vi-
tamin D deficiency to be used in Saudi Arabia, the group of
populations most eligible for screening, method of measurement
and type, dose and duration of supplementation depending on
vitamin D deficiency severity, and other accompanying risk
factors.
Definition of vitamin D deficiency
The most common definitions used for the diagnosis of vitamin
D statuses are described in Table 1. While the cutoffs vary with
respect to who is vitamin D deficient, most of the major interna-
tional institutions that have endorsed them are in agreement that
patients whose serum 25(OH)D levels fall below 50 nmol/l
(20 ng/ml) require correction [1–5, 9]. Hence, the consensus of
local experts is to adapt the following cutoffs on the basis of
impact on bone health:
& Deficiency—serum 25(OH)D < 50 nmol/l (<20 ng/ml).
& Sufficiency—serum 25(OH)D ≥ 50 nmol/l (≥20 ng/ml).
& Adequacy for frail, osteoporotic elderly—serum
25(OH)D > 75 nmol/l (>30 ng/ml).
The recommended cutoff for vitamin D sufficiency that is
much lower than the one advocated by the US Endocrine
Society [25(OH)D > 75 nmol/l (>30 ng/ml)] was also based on
several local observational studies that noted normal levels of
PTH despite severely low levels of circulating 25(OH)D [19],
lack of association between intact PTH and 25(OH)D [20], and
the absence of 25(OH)D threshold at which PTH level suppres-
sion is evident [21]. This apparent confusion is also related to the
target, i.e., the general population or frail, osteoporosis, possibly
undernourished elderly. Nevertheless, elevated PTH levels in
response to low 25(OH)D among healthy Saudis were observed
only at the Binsufficient^ cutoff (<50 nmol/l or 20 ng/ml), al-
though inconsistent and at varying degrees, depending on the
method used [22]. This threshold for insufficiency reinforces an
earlier large-scale study which was also done in the Middle-East
last 2011, that a 25(OH)D threshold of 50 nmol/l is enough for
PTH suppression, at least among subjects with normal renal
function, for the prevention of secondary hyperparathyroidism
[23]. These more recent findings supersede the earlier consensus
of using 25(OH)D < 37.5 nmol/l (15 ng/ml) for the MENA
region (2007) [24] and <70 nmol (28 ng/ml) (for KSA (2011)
[25] as cutoffs for vitamin D insufficiency.
Who are eligible for vitamin D screening?
Despite overwhelming evidence that vitamin D deficiency is
common in the Saudi community across all age groups, vitamin
D testing for the general population is not justified and practical
in economic terms. Hence, the task force does not endorse
population-based screening and recommends limited vitamin D
testing for selected populations at highest risk for vitamin D
deficiency and who will benefit the most from vitamin D status
correction.
& Patients with clinical suspicion of rickets, osteopenia, os-
teomalacia, and osteoporosis
& Patients with history of fall and fragility fracture
& Patients with musculoskeletal pain and fibromyalgia
& Elderly patients
& Patients with malabsorption syndromes (e.g., inflammato-
ry bowel diseases, celiac diseases)
& Patients with renal/liver diseases
& Home-based patients with minimal access to sun exposure




& Poor exposure to sunlight due to social/clothing habits
Table 1 Most commonly used vitamin D status definitions
International
agencies
Deficiency Insufficiency Sufficiency Toxicity
US Endocrine Societya
International Osteoporosis Foundation
US National Osteoporosis Foundation
American Geriatric Society
nmol/l <50 52.5–72.5 75 >250
ng/ml <20 21–29 30 >100
US Institute of Medicinea
UK National Osteoporosis Society
nmol/l <30 30–50 ≥50 >125




nmol/l <25 <50 >50
ng/ml <10 <20 >20
ESCEOa
nmol/l <25 50–75 >75 >125
ng/ml <10 20–30 >30 >50
a The agency who established the definition. While definitions vary, the
criteria for optimal vitamin D status have been based primarily in the
following: maximal suppression of PTH, adequate intestinal calcium ab-
sorption, and fracture prevention
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& Medications that affect bone bones (e.g., glucocorticoids,
antiepileptic medications)
& Postbariatric surgery.
High-risk minority groups mentioned above with a confirmed
diagnosis of vitamin D deficiency should receive higher than
normal doses than the general population. While other non-
skeletal metabolic abnormalities linked to vitamin D deficiency
in the Saudi population such as obesity [26], metabolic syndrome
[27], type 2 diabetes mellitus [28], and auto-immune diseases
[29] may benefit from vitamin D status correction, mandatory
screening is not recommended unless the patient has other risk
factors and clinical features consistent with the ones mentioned
above.
Vitamin D measurement
It has been established that circulating total 25(OH)D (including
both D2 and D3 forms) is the best marker for vitamin D status as
compared to other metabolites. Nonetheless, with the increase in
the possible number of methods to assess vitamin D status, dis-
crepancies in the validity and reliability of results were inevitable
and still exist despite efforts for standardization, making reported
prevalence in a given cohort largely dependent on the method
used [30–32]. Currently, the liquid chromatography–tandem
mass spectrometry (LC-MS/MS) is the gold standard for mea-
suring total 25(OH)D and other vitamin D metabolites for its
high sensitivity and selectivity [33]. In major tertiary hospitals
in KSA however, automated immunometric assays are preferred
and major differences in results have been confirmed in local
studies, mostly by Sadat and colleagues [22, 34, 35]. Well-
known standardization systems include the Vitamin D External
Quality Assessment Scheme (DEQAS) [36], of which PMCO in
KSU is an accredited partner. The task force recommends caution
in the interpretation and treatment of patient’s vitamin D status in
cases where the reliability of method used is questionable, espe-
cially in the absence of other clinical features and risk factors
consistent with the skeletal effects of chronic vitamin D deficien-
cy. The task force also recommends standardization of serum
25(OH)D tests and other vitamin D metabolites in all clinical
laboratories in Saudi Arabia from internationally recognized ac-
creditation agencies such as College of American Pathologists
(CAP) and DEQAS, among others.
Vitamin D correction in the general population
Sun exposure
Adequate sun exposure is recommended for the general pop-
ulation. In Saudi Arabia however, the most suitable times are
as follows: summer time from 9:00 AM until before
10:30 AM as well as 2:00 PM until 3:00 PM and winter time
from 10 AM to 2 PM [37], three to four times a week. People
should directly expose their hands and legs to sunlight (20%
of their bodies). Those with darker complexion may need
more sunlight exposure time to get vitamin D. Routine mon-
itoring of serum 25(OH)D is generally unnecessary but may
be appropriate in patients with symptomatic vitamin D defi-
ciency or malabsorption and where poor compliance with
medication is suspected.
Dietary sources and food fortification
Table 2 shows the list of vitamin D-rich foods based on the US
Department of Agriculture’s Nutrient Database website [38], a
strong evidence that milk and orange juice can be an effective
vehicle for vitamin D fortification. Consumption of the forti-
fied milk for 24 months significantly increased serum
25(OH)D and effectively reduced bone loss at the lumbar
spine and hip [39]. Food fortification with vitamin D is sub-
mitted to the need of an efficacious quality control.
Pregnant/lactating mothers and neonates
A poor vitamin D status during pregnancy is being common-
ly recognized all over the world especially in the Middle East
Gulf States and North African countries [24]. The World
Health Organization in collaboration with the executive com-
mittee of 18th Vitamin D Workshop organized a joint sym-
posium on the prevention and consequences of vitamin D
deficiency in pregnant women and children [40]. They
highlighted the importance of advice on vitamin D as a part
of antenatal care. They acknowledge the lack of consensus
on the required intake for this group and endorsed the
Institute of Medicine (IOM) recommendation for 600 IU
but encouraged research and population-based specific ap-
proaches in countries with the poorest documented vitamin
D status. De-Regli and colleagues highlighted that vitamin D
supplementation as routine part of antenatal care in improv-
ing maternal and fetal outcomes remain unclear, but there are
inconclusive indications that correcting vitamin D status at
term may reduce preeclampsia risk, low birth weight, and
preterm birth [41]. In a recent systematic review that inves-
tigated the vitamin D concentrations of pregnant women in
the Mediterranean region (Spain, Italy, Greece, and Turkey),
up to 90% of mothers (N = 2649) and neonates (N = 1820)
were deficient according to the less conservative criteria of
the IOM (<50 nmol/l or <20 ng/ml) [42]. From the same
cutoff, vitamin D deficiency among Saudi pregnant women
ranges from 90 to 100% [43, 44].
Different recommendations and guidelines ranging from
400 IU (UK Royal College of Obstetrics and Gynecology)
to 2000 IU (Canadian Academy of Pediatrics) and even
4000 IU have been documented [45]. In the case of Saudi
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Arabia, low vitamin D is very common in pregnancy with
consequences for both mothers and babies; therefore, supple-
mentation of 1000–2000 IU/day can be recommended and is
both feasible and safe.
Postmenopausal women
Most organizations recommend that healthy postmenopausal
women over the age of 65 years should receive 800–1000 IU/
day of vitamin D to maintain sufficient serum 25(OH)D levels
[9]. The task force believes that this dose is suboptimal in the
Gulf region. Vitamin D supplements should be used when diet
and lifestyle (sunlight) recommendations cannot be implement-
ed, which is generally the case in this class of the population.
Postmenopausal who are severely vitamin D deficient
(<25 nmol/l or 10 ng/ml) can be treated with 50,000 IU of
vitamin D2 or vitamin D3 once a week for 8 weeks or its
equivalent of 6000 IU of vitamin D2 or vitamin D3 daily for
8 weeks followed by maintenance therapy of 1000–2000 IU/
day after the serum 25(OH)D level is above 75 nmol/l.
Furthermore, to sustain this level, maintenance therapy of
1500–2000 IU/D might be required [1]. Indeed, higher doses
are needed in obese, postbariatric surgery, patients with mal-
absorption syndromes, and patients on medications affecting
vitamin Dmetabolism at least 6000–10,000 IU/day of vitamin
D [followed by maintenance therapy of 3000–6000 IU/day
after the serum 25(OH)D level is above 30 ng/ml (75 nmol/
l)] [1]. High doses of vitamin D would require some monitor-
ing of 25(OH)D to avoid overdose.
Recommendations for postmenopausal women
& Postmenopausal with severe vitamin D deficiency
(<25 nmol/l or 10 ng/ml) can be treated with 50,000 IU
once weekly (vitamin D2 or vitamin D3) for 8 weeks or
6000 IU/day (vitamin D2 or vitamin D3) (followed by
maintenance therapy of 1000–2000 IU/day once serum
25(OH)D level is above 75 nmol/l or 30 ng/ml).
& In healthy postmenopausal women, adequate serum con-
centrations can be achieved through sun exposure (15 min
per day, three to four times a week).
& Patients with morbid obesity, postbariatric surgery, malab-
sorption syndromes, and hepatic or renal diseases may
require larger than usual doses of vitamin D supplements.
In such patients, routine monitoring of serum 25(OH)D
may be appropriate.
Elderly and patients at risk for fall and osteoporotic
fractures
Although sun exposure has been recommended to improve the
status of vitamin D in the general population, this way of natural
correction may not be practical in the Saudi elderly. In addition,
this may be feasible only in winter months where temperatures
are tolerable. Foods consumed in SaudiArabia have little vitamin
D fortification. For vitamin D deficiency, supplementation is the
most guaranteed way to increase levels to the desired range of
50–75 nmol/l. This can be achieved by weekly 50,000 IU for
8 weeks followed by daily maintenance of daily 1000–2000 IU
[46]. Annual mega dosing by intramuscular injections of vitamin
D are not recommended as these dosage forms may not be read-
ily available in all hospitals in KSA and their efficacy is disputed.
Ayearly dose of 500,000 IU has been shown to increase the risk
of falls and of fractures [47].
For patients at high risk for falls and osteoporotic fractures, the
same recommendations mentioned above are applicable; howev-
er, the desired 25(OH)D level should be at least 75 nmol/l (30 ng/
ml). Furthermore, concomitant supplementation with calcium is
advised only for those with known calcium insufficiency and
Table 2 Selected dietary sources
of vitamin D Food IUs/serving Percent of
daily value
Cod liver oil, 1 tablespoon 1360 340
Swordfish, cooked, 3 oz 566 142
Salmon, cooked, 3 oz 447 112
Tuna fish, canned in water, drained, 3 oz 154 39
Orange juice fortified with vitamin D, 1 cup 137 34
Milk, nonfat, reduced fat, and whole, vitamin D-fortified, 1 cup 115–124 29–31
Yogurt fortified with 20% of the DV for vitamin D, 6 oz
(more heavily fortified yogurts provide more of the DV)
80 20
Sardines, canned in oil, drained, 2 sardines 46 12
Liver, beef, cooked, 3 oz 42 11
Egg, 1 large (vitamin D is found in yolk) 41 10
Cheese, Swiss, 1 oz 6 2
DV daily value
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those who are already undergoing treatment for osteoporosis
[48].
Patients with metabolic diseases
It has been a common feature of Saudi patients with chronic
metabolic diseases (diabetes mellitus, obesity, thyroid problems,
etc.) to have insufficient levels of serum 25(OH)D. Interventional
studies done by Al-Daghri and colleagues in the Saudi popula-
tion with metabolic disorders observed that while doses as much
as 2000 IU/day for 12–18 months are still suboptimal, it did
confer favorable metabolic changes in terms of improved lipid
profile and insulin sensitivity [27, 49]. Jafari and colleagues in
their recent meta-analysis had similar findings that vitamin D
correction improves the serum lipid profile of patients with dia-
betes [50]. Krul-Poel et al. however has shown no conclusive
evidence from gathered clinical trials that support favorable gly-
cemic control through vitamin D supplementation among pa-
tients with diabetes [51].
In light of inconclusive observations from accumulated
clinical trials, the task force therefore recommends no spe-
cial consideration among patients with metabolic diseases
and would manage asymptomatic vitamin D deficiency in
the same case as the general population until further evi-
dence emerges.
Children and adolescents
Vitamin D deficiency is extremely common in the pediatric pop-
ulation of Saudi Arabia [52]. Adolescent females in particular
have a higher prevalence of vitamin D deficiency than males
and are at higher risk of osteomalacia [53].
The pragmatic use of a serum 25(OH)D concentration
more than or equal to 30 ng/ml (>75 nmol/l) to indicate suffi-
ciency and a serum concentration < 25 nmol/l (10 ng/ml) to
indicate severe deficiency is recommended. All Saudi children
and adolescents, females especially, are encouraged to receive
oral supplementation of vitamin D as follows:
& Premature infants, 400–800 IU/day
& Infants 0–6 months, 400 IU/day
& Infants 6–12 months, 400–600 IU/day
& Children/adolescents, 600–1000 IU/day
& Obese children, 1200–2000 IU/day.
The upper limit of safety is set at
& 1000 IU/day for infants
& 2000 IU/day for children ages 1 to 10 years
& 4000 IU/day for children and adolescents ages 11–
17 years.
For those in high-risk groups (preterm babies; darker color;
obese; with malnutrition and malabsorption syndromes; those on
medications like antiepileptic, antituberculosis, and glucocorti-
coids), oral supplementation of vitamin D must be considered.
Universal screening for vitamin D status in the Saudi pediatric
population is not advised, and monitoring should be kept at a
minimum with special attention to children manifesting severe
symptoms of vitamin D deficiency.
Conclusion
The PMCO task force in cooperation with the ESCEO working
group has addressed all themajor aspects of vitaminD deficiency
management in the Saudi population and endorses its consensus
statements for general clinical practice not only in Saudi Arabia
but in the Middle East in general. Vitamin D supplementation/
correction is advised in all persons whose serum 25(OH)D falls
below 50 nmol/l (20 ng/ml), and achieving a target of 75 nmol/l
(30 ng/ml) is particularly suited for frail, osteoporotic, and older
patients. The group also encourages conducting well-designed
clinical trials in the region that will address risks and benefits,
economic implications of vitamin D status correction and inves-
tigations on the treatment persistence, and compliance to vitamin
D treatment in the region. The final recommendations assigned
were based on the best available evidence at the time of submis-
sion of these guidelines to the journal.
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